Leflunomide Mylan ( DrugBank: Leflunomide )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

53. シェーグレン症候群

---

臨床試験数 : 283 /  薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-003140-12-NL (EUCTR)	21/09/2015	26/08/2015	Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome	Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF-HCQ combination therapy in pSS	Sjogren's Syndrome MedDRA version: 18.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;Classification code 10042846;Term: Syndrome Sjogren's;Classification code 10040765;Term: Sjogren's;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Leflunomide Mylan Product Name: Leflunomide mylan INN or Proposed INN: LEFLUNOMIDE Trade Name: Plaquenil Product Name: Plaquenil INN or Proposed INN: HYDROXYCHLOROQUINE	UMC Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no			Netherlands